Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis.

Katz G

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme23 May 2025Cited by 1 (Europe PMC)

PMID40409279DOI10.1055/a-2569-7315PepBankPUB-40409279

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

01HumanSystematic reviewEfficacy outcome
In a meta-analysis in type 2 diabetes, semaglutide reduced HbA1c by a mean of 1.45%.
In plain wordsIn a pooled analysis of studies in type 2 diabetes, semaglutide lowered HbA1c by about 1.45%.
Peptide
Semaglutide
Outcome
DecreaseMean HbA1c reduction
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
HbA1c reduction
1.45%
semaglutide
Source sentences
Summary
Semaglutide demonstrated superior efficacy with mean HbA1c reduction of 1.45% and weight loss of 1.44 kg.
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive search of PubMed/MEDLINE, Embase, Cochrane Library, Scopus, and Web of Science (2015-2023) identified 20 randomized controlled trials and observational studies.
Report a problemFND-4040927901
02HumanSystematic reviewEfficacy outcome
In a meta-analysis in type 2 diabetes, semaglutide reduced body weight by 1.44 kg.
In plain wordsIn a pooled analysis of studies in type 2 diabetes, semaglutide lowered body weight by about 1.44 kg.
Peptide
Semaglutide
Outcome
DecreaseWeight loss
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Weight loss
1.44 kg
semaglutide
Source sentences
Summary
Semaglutide demonstrated superior efficacy with mean HbA1c reduction of 1.45% and weight loss of 1.44 kg.
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive search of PubMed/MEDLINE, Embase, Cochrane Library, Scopus, and Web of Science (2015-2023) identified 20 randomized controlled trials and observational studies.
Report a problemFND-4040927902
03HumanSystematic reviewSafety outcome
In a meta-analysis in type 2 diabetes, gastrointestinal side effects were most common, and semaglutide showed the highest incidence among the three GLP-1 receptor agonists.
In plain wordsIn a pooled analysis, stomach and bowel side effects were most common, and semaglutide had the highest rate among the three drugs.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal side effects
Study
n: not reported in source
Comparator
Dulaglutide and exenatide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Gastrointestinal side effects were most common, with Semaglutide showing the highest incidence.
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive search of PubMed/MEDLINE, Embase, Cochrane Library, Scopus, and Web of Science (2015-2023) identified 20 randomized controlled trials and observational studies.
Report a problemFND-4040927903

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In a meta-analysis in type 2 diabetes, the pooled GLP-1 receptor agonists (semaglutide, dulaglutide, exenatide) lowered HbA1c, with a mean difference of -0.81.
In plain wordsPooled across semaglutide, dulaglutide and exenatide, GLP-1 drugs lowered HbA1c in type 2 diabetes.
Peptide
Semaglutide
Outcome
DecreasePooled HbA1c difference for GLP-1 receptor agonists
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
Mean HbA1c difference
−0.81%
pooled GLP-1 RAs
Source sentences
Summary
Meta-analysis revealed a significant pooled effect estimate favoring GLP-1 receptor agonists. with a mean HbA1c difference of -0.81 (95% CI: -0.92 to -0.70).
1 context sentence(design, population, supporting numbers)
Summary · context
A comprehensive search of PubMed/MEDLINE, Embase, Cochrane Library, Scopus, and Web of Science (2015-2023) identified 20 randomized controlled trials and observational studies.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4040927904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.